在无糖尿病病史的患者中，成纤维细胞生长因子 21 与心血管风险和β细胞功能的相关性。
Associations of fibroblast growth factor 21 with cardiovascular risk and β-cell function in patients who had no history of diabetes.
机构信息
Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan; Institute of Medical Technology, College of Life Science, National Chung-Hsing University, Taichung, Taiwan; School of Medicine, National Defense Medical Center, Taipei, Taiwan.
出版信息
Clin Chim Acta. 2017 Sep;472:80-85. doi: 10.1016/j.cca.2017.07.017. Epub 2017 Jul 19.
BACKGROUND
We investigated the associations of fibroblast growth factor 21 (FGF-21) with cardiovascular risk and β-cell function in patients who had no history of diabetes.
METHODS
We enrolled 269 outpatients who had been referred for an oral glucose tolerance test (OGTT). Plasma glucose, insulin, and FGF-21 were measured before and at 2h after the OGTT. β-cell function was assessed using the insulinogenic index, corrected for insulin resistance. Patients' 10-year coronary heart disease (CHD) risk was assessed using the Chinese Multi-provincial Cohort Study functions.
RESULTS
Overall, there was a 10% decrease in FGF-21 after OGTT (p<0.001). The decrease of FGF-21 after OGTT in patients with normal glucose tolerance, prediabetes, and diabetes was 8%, 10%, and 21%, respectively (all p<0.05). Patients with a history of admission for coronary angiography had a higher 10-year CHD risk and fasting FGF-21 (both p<0.001). In multivariate regression analysis, fasting FGF-21 was positively associated with 10-year CHD risk, while FGF-21 relative change 2h after OGTT was positively associated with β-cell function.
CONCLUSIONS
In patients who had no history of diabetes, fasting FGF-21 was positively associated with 10-year CHD risk, while FGF-21 relative change 2h after OGTT was positively associated with β-cell function.
背景
我们研究了成纤维细胞生长因子 21（FGF-21）与无糖尿病病史患者的心血管风险和β细胞功能的相关性。
方法
我们纳入了 269 名因口服葡萄糖耐量试验（OGTT）而就诊的门诊患者。在 OGTT 前和 2 小时后测量血糖、胰岛素和 FGF-21。β细胞功能通过胰岛素原指数评估，并校正了胰岛素抵抗。使用中国多省份队列研究功能评估患者的 10 年冠心病（CHD）风险。
结果
总体而言，OGTT 后 FGF-21 降低了 10%（p<0.001）。在糖耐量正常、糖尿病前期和糖尿病患者中，OGTT 后 FGF-21 的降低分别为 8%、10%和 21%（均 p<0.05）。有冠状动脉造影入院史的患者的 10 年 CHD 风险和空腹 FGF-21 更高（均 p<0.001）。多元回归分析显示，空腹 FGF-21 与 10 年 CHD 风险呈正相关，而 OGTT 后 2 小时 FGF-21 的相对变化与β细胞功能呈正相关。
结论
在无糖尿病病史的患者中，空腹 FGF-21 与 10 年 CHD 风险呈正相关，而 OGTT 后 2 小时 FGF-21 的相对变化与β细胞功能呈正相关。
Zotero 插件